Celldex Therapeutics, Inc. (CLDX)
USD 14.93
(-5.42%)
USD 14.93
(-5.42%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -139.03 Million USD | -36.49% |
| 2022 | -104.2 Million USD | -50.78% |
| 2021 | -66.08 Million USD | -76.87% |
| 2020 | -45.64 Million USD | 34.34% |
| 2019 | -49.66 Million USD | -9060.94% |
| 2018 | -72.6 Million USD | 99.34% |
| 2017 | -104.01 Million USD | 29.55% |
| 2016 | -124.43 Million USD | -4.15% |
| 2015 | -125.53 Million USD | -7.79% |
| 2014 | -116.52 Million USD | -54.68% |
| 2013 | -77.67 Million USD | -37.75% |
| 2012 | -54.41 Million USD | -35.74% |
| 2011 | -38.84 Million USD | -1167.57% |
| 2010 | 4.66 Million USD | 90.06% |
| 2009 | -33.07 Million USD | -85.49% |
| 2008 | -44.96 Million USD | 15.53% |
| 2007 | -19.07 Million USD | 5.01% |
| 2006 | -18.15 Million USD | -27.89% |
| 2005 | -16.5 Million USD | -42.95% |
| 2004 | -11.81 Million USD | -17.21% |
| 2003 | -10.2 Million USD | 22.11% |
| 2002 | -12.8 Million USD | 44.38% |
| 2001 | -22.3 Million USD | -217.45% |
| 2000 | -14.13 Million USD | 28.28% |
| 1999 | -9.95 Million USD | -128.7% |
| 1998 | -6.94 Million USD | 2150.0% |
| 1997 | -7.3 Million USD | 85.37% |
| 1996 | -11.3 Million USD | 16.33% |
| 1995 | -11.1 Million USD | -122.73% |
| 1994 | -8.7 Million USD | 31.96% |
| 1993 | -8.5 Million USD | -97.96% |
| 1992 | -4.1 Million USD | -4.26% |
| 1991 | -5.9 Million USD | -55.26% |
| 1990 | -3.8 Million USD | -171.43% |
| 1989 | -1.4 Million USD | -7.69% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -45.52 Million USD | -14.28% |
| 2024 Q1 | -39.83 Million USD | -15.9% |
| 2023 Q3 | -43.45 Million USD | -21.01% |
| 2023 Q1 | -35.58 Million USD | -21.51% |
| 2023 Q4 | -34.36 Million USD | 20.9% |
| 2023 Q2 | -35.9 Million USD | -0.92% |
| 2023 FY | - USD | -36.49% |
| 2022 FY | - USD | -50.78% |
| 2022 Q1 | -23.72 Million USD | -12.85% |
| 2022 Q2 | -18.69 Million USD | 21.18% |
| 2022 Q3 | -27.93 Million USD | -49.4% |
| 2022 Q4 | -29.28 Million USD | -4.82% |
| 2021 Q3 | -17.01 Million USD | -39.19% |
| 2021 Q4 | -21.02 Million USD | -23.53% |
| 2021 FY | - USD | -76.87% |
| 2021 Q2 | -12.22 Million USD | 18.48% |
| 2021 Q1 | -14.99 Million USD | -747.9% |
| 2020 FY | - USD | 34.34% |
| 2020 Q2 | -13.58 Million USD | -18.39% |
| 2020 Q3 | -12.27 Million USD | 9.66% |
| 2020 Q4 | 2.31 Million USD | 118.86% |
| 2020 Q1 | -11.47 Million USD | 22.95% |
| 2019 Q3 | -15.29 Million USD | -12.33% |
| 2019 FY | - USD | -9060.94% |
| 2019 Q1 | -10.65 Million USD | 41.3% |
| 2019 Q2 | -13.61 Million USD | -27.81% |
| 2019 Q4 | -14.89 Million USD | 2.62% |
| 2018 Q3 | -21.32 Million USD | 31.69% |
| 2018 Q4 | -18.14 Million USD | 14.88% |
| 2018 Q1 | 72.9 Million USD | 359.59% |
| 2018 Q2 | -31.21 Million USD | -142.81% |
| 2018 FY | - USD | 99.34% |
| 2017 Q2 | -26.06 Million USD | 5.47% |
| 2017 Q4 | -28.08 Million USD | -96.25% |
| 2017 FY | - USD | 29.55% |
| 2017 Q1 | -27.57 Million USD | 25.8% |
| 2017 Q3 | -14.31 Million USD | 45.1% |
| 2016 Q2 | -31.83 Million USD | 10.93% |
| 2016 FY | - USD | -4.15% |
| 2016 Q4 | -37.16 Million USD | -23.32% |
| 2016 Q1 | -35.74 Million USD | -5.31% |
| 2016 Q3 | -30.13 Million USD | 5.34% |
| 2015 FY | - USD | -7.79% |
| 2015 Q1 | -31.53 Million USD | 0.83% |
| 2015 Q4 | -33.93 Million USD | -6.92% |
| 2015 Q2 | -32.17 Million USD | -2.03% |
| 2015 Q3 | -31.74 Million USD | 1.35% |
| 2014 Q2 | -28.29 Million USD | 7.7% |
| 2014 Q4 | -31.79 Million USD | -5.68% |
| 2014 FY | - USD | -54.68% |
| 2014 Q1 | -30.65 Million USD | -43.59% |
| 2014 Q3 | -30.08 Million USD | -6.34% |
| 2013 FY | - USD | -37.75% |
| 2013 Q1 | -17.14 Million USD | -5.23% |
| 2013 Q4 | -21.35 Million USD | 5.26% |
| 2013 Q3 | -22.53 Million USD | -25.7% |
| 2013 Q2 | -17.92 Million USD | -4.55% |
| 2012 Q1 | -13.2 Million USD | -18.05% |
| 2012 Q4 | -16.29 Million USD | -11.6% |
| 2012 FY | - USD | -35.74% |
| 2012 Q3 | -14.6 Million USD | -9.6% |
| 2012 Q2 | -13.32 Million USD | -0.92% |
| 2011 Q3 | -10.96 Million USD | -15.71% |
| 2011 FY | - USD | -1167.57% |
| 2011 Q1 | -8.79 Million USD | -134.55% |
| 2011 Q4 | -11.18 Million USD | -1.98% |
| 2011 Q2 | -9.47 Million USD | -7.73% |
| 2010 Q3 | -8.52 Million USD | -6.19% |
| 2010 Q2 | -8.02 Million USD | 20.89% |
| 2010 Q4 | 25.45 Million USD | 398.8% |
| 2010 Q1 | -10.14 Million USD | 14.14% |
| 2010 FY | - USD | 90.06% |
| 2009 FY | - USD | -85.49% |
| 2009 Q1 | -7.08 Million USD | 15.49% |
| 2009 Q2 | -7.99 Million USD | -12.8% |
| 2009 Q3 | -6.42 Million USD | 19.65% |
| 2009 Q4 | -11.81 Million USD | -83.86% |
| 2008 Q3 | -7.76 Million USD | 18.68% |
| 2008 FY | - USD | 15.53% |
| 2008 Q1 | 7.69 Million USD | 259.64% |
| 2008 Q4 | -8.38 Million USD | -8.02% |
| 2008 Q2 | -9.54 Million USD | -224.15% |
| 2007 Q4 | -4.81 Million USD | 2.43% |
| 2007 Q1 | -5.93 Million USD | 15.04% |
| 2007 Q3 | -4.93 Million USD | 11.45% |
| 2007 FY | - USD | 5.01% |
| 2007 Q2 | -5.57 Million USD | 6.0% |
| 2006 Q4 | -6.98 Million USD | -12.14% |
| 2006 FY | - USD | -27.89% |
| 2006 Q1 | -2.68 Million USD | 30.45% |
| 2006 Q2 | -6.48 Million USD | -141.47% |
| 2006 Q3 | -6.22 Million USD | 4.03% |
| 2005 FY | - USD | -42.95% |
| 2005 Q4 | -3.86 Million USD | 8.83% |
| 2005 Q3 | -4.23 Million USD | 9.12% |
| 2005 Q2 | -4.66 Million USD | 0.95% |
| 2005 Q1 | -4.7 Million USD | -36.3% |
| 2004 FY | - USD | -17.21% |
| 2004 Q2 | -3.67 Million USD | -130.21% |
| 2004 Q4 | -3.45 Million USD | 1.94% |
| 2004 Q3 | -3.52 Million USD | 4.12% |
| 2004 Q1 | -1.59 Million USD | 40.72% |
| 2003 Q1 | -3.04 Million USD | 4.21% |
| 2003 Q2 | -2.74 Million USD | 13.2% |
| 2003 FY | - USD | 22.11% |
| 2003 Q3 | -1.71 Million USD | 35.72% |
| 2003 Q4 | -2.69 Million USD | -52.12% |
| 2002 Q2 | -4.92 Million USD | -4.03% |
| 2002 Q4 | -3.19 Million USD | -2615.91% |
| 2002 Q1 | -4.68 Million USD | 28.06% |
| 2002 Q3 | -600.00 USD | 97.6% |
| 2002 FY | - USD | 44.38% |
| 2001 Q2 | -5.58 Million USD | -35.76% |
| 2001 Q3 | -6.03 Million USD | -5.18% |
| 2001 Q4 | -6.52 Million USD | -6.28% |
| 2001 FY | - USD | -217.45% |
| 2001 Q1 | -4.48 Million USD | -303.44% |
| 2000 FY | - USD | 28.28% |
| 2000 Q2 | -2.68 Million USD | 12.11% |
| 2000 Q1 | -2.58 Million USD | 13.63% |
| 2000 Q3 | -4.02 Million USD | -36.39% |
| 2000 Q4 | -4.83 Million USD | 154.67% |
| 1999 Q3 | -2.1 Million USD | -10.0% |
| 1999 FY | - USD | -128.7% |
| 1999 Q1 | -2.4 Million USD | -18.18% |
| 1999 Q4 | -3.65 Million USD | -76.86% |
| 1999 Q2 | -1.95 Million USD | 23.08% |
| 1998 Q1 | -1.4 Million USD | 16.67% |
| 1998 Q2 | -1.5 Million USD | -20.0% |
| 1998 Q3 | -2.1 Million USD | 2455.56% |
| 1998 FY | - USD | 2150.0% |
| 1998 Q4 | -1.9 Million USD | -105.19% |
| 1997 Q3 | -2 Million USD | 300.0% |
| 1997 Q1 | -1.9 Million USD | 27.59% |
| 1997 Q2 | -1.8 Million USD | 4.76% |
| 1997 Q4 | -1.6 Million USD | -145.0% |
| 1997 FY | - USD | 85.37% |
| 1996 Q1 | -2.1 Million USD | 58.33% |
| 1996 FY | - USD | 16.33% |
| 1996 Q4 | -2.6 Million USD | -26.09% |
| 1996 Q3 | -2.1 Million USD | 47.73% |
| 1996 Q2 | -4.3 Million USD | -76.0% |
| 1995 Q1 | -2.5 Million USD | -1000.0% |
| 1995 Q2 | -2.5 Million USD | 0.0% |
| 1995 FY | - USD | -122.73% |
| 1995 Q4 | -2.9 Million USD | -81.82% |
| 1995 Q3 | -3.2 Million USD | -22.22% |
| 1994 Q3 | -2.3 Million USD | 29.63% |
| 1994 Q2 | -2.4 Million USD | -8.0% |
| 1994 Q1 | -2.1 Million USD | -8.7% |
| 1994 FY | - USD | 31.96% |
| 1994 Q4 | -2 Million USD | 115.79% |
| 1993 Q2 | -1.8 Million USD | 12.5% |
| 1993 Q4 | -2.1 Million USD | 14.81% |
| 1993 Q1 | -2 Million USD | 0.0% |
| 1993 Q3 | -2.7 Million USD | -28.57% |
| 1993 FY | - USD | -97.96% |
| 1992 Q1 | -1.7 Million USD | -81.82% |
| 1992 Q2 | -1.4 Million USD | 15.0% |
| 1992 FY | - USD | -4.26% |
| 1992 Q3 | -1.1 Million USD | 17.65% |
| 1991 Q3 | -1.9 Million USD | -20.0% |
| 1991 FY | - USD | -113.64% |
| 1991 Q2 | -1.6 Million USD | -42.86% |
| 1991 Q1 | -1.1 Million USD | -27.27% |
| 1991 Q4 | -700 Thousand USD | 54.17% |
| 1990 Q1 | 200 Thousand USD | 0.0% |
| 1990 FY | - USD | -10.0% |
| 1990 Q4 | -900 Thousand USD | -10.0% |
| 1990 Q3 | -800 Thousand USD | 23.08% |
| 1990 Q2 | -1.1 Million USD | -1200.0% |
| 1989 Q4 | -100 Thousand USD | -104.17% |
| 1989 Q1 | -7.1 Million USD | -473.68% |
| 1989 FY | - USD | 23.08% |
| 1989 Q3 | 2.4 Million USD | 14.29% |
| 1989 Q2 | 2.1 Million USD | 129.58% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| AbCellera Biologics Inc. | -192.15 Million USD | 27.646% |
| Alkermes plc | 495.04 Million USD | 128.085% |
| Agenus Inc. | -145.92 Million USD | 4.722% |
| Aptorum Group Limited | -9.59 Million USD | -1348.422% |
| Ardelyx, Inc. | -55.35 Million USD | -151.172% |
| Dyadic International, Inc. | -8.22 Million USD | -1589.41% |
| Eton Pharmaceuticals, Inc. | -291 Thousand USD | -47678.007% |
| Lantern Pharma Inc. | -15.78 Million USD | -780.704% |
| Inhibikase Therapeutics, Inc. | -19.91 Million USD | -598.228% |
| Novavax, Inc. | -487.39 Million USD | 71.474% |
| Janux Therapeutics, Inc. | -71.02 Million USD | -95.756% |
| Pyxis Oncology, Inc. | -78.49 Million USD | -77.129% |
| TransCode Therapeutics, Inc. | -17.97 Million USD | -673.552% |
| Ocuphire Pharma, Inc. | -9.96 Million USD | -1294.803% |
| Outlook Therapeutics, Inc. | -57.37 Million USD | -142.321% |
| Madrigal Pharmaceuticals, Inc. | -379.96 Million USD | 63.409% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.11 Million USD | -476.62% |
| SELLAS Life Sciences Group, Inc. | 529 Thousand USD | 26382.42% |
| Syros Pharmaceuticals, Inc. | -157.19 Million USD | 11.553% |
| Barinthus Biotherapeutics plc | -74.81 Million USD | -85.837% |
| Windtree Therapeutics, Inc. | -20.15 Million USD | -589.687% |
| Xeris Biopharma Holdings, Inc. | -23.73 Million USD | -485.776% |
| Clearside Biomedical, Inc. | -23.05 Million USD | -502.975% |
| C4 Therapeutics, Inc. | -122.1 Million USD | -13.866% |
| Alnylam Pharmaceuticals, Inc. | -258.24 Million USD | 46.161% |
| AlloVir, Inc. | -190.14 Million USD | 26.88% |
| Arrowhead Pharmaceuticals, Inc. | -175.67 Million USD | 20.856% |
| VYNE Therapeutics Inc. | -29.25 Million USD | -375.2% |
| Bicycle Therapeutics plc | -183.4 Million USD | 24.191% |
| BioXcel Therapeutics, Inc. | -165.42 Million USD | 15.951% |
| ChromaDex Corporation | -3.89 Million USD | -3470.467% |
| Chimerix, Inc. | -92.97 Million USD | -49.541% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.43 Million USD | -212.881% |
| Caribou Biosciences, Inc. | -112.53 Million USD | -23.548% |
| CRISPR Therapeutics AG | -202.7 Million USD | 31.409% |
| Precision BioSciences, Inc. | -32.04 Million USD | -333.912% |
| Fate Therapeutics, Inc. | -172.22 Million USD | 19.274% |
| Fortress Biotech, Inc. | -133.64 Million USD | -4.034% |
| Fortress Biotech, Inc. | -133.64 Million USD | -4.034% |
| HOOKIPA Pharma Inc. | -77.34 Million USD | -79.763% |
| ImmuCell Corporation | -2.5 Million USD | -5452.305% |
| IDEAYA Biosciences, Inc. | -130.42 Million USD | -6.604% |
| Immix Biopharma, Inc. | -16.13 Million USD | -761.658% |
| Incyte Corporation | 919.42 Million USD | 115.122% |
| Innoviva, Inc. | 248.96 Million USD | 155.846% |
| IO Biotech, Inc. | -91.22 Million USD | -52.403% |
| Jaguar Health, Inc. | -33.13 Million USD | -319.649% |
| Keros Therapeutics, Inc. | -152.17 Million USD | 8.637% |
| Ligand Pharmaceuticals Incorporated | 101.72 Million USD | 236.674% |
| ContextLogic Inc. | -324 Million USD | 57.088% |
| MiMedx Group, Inc. | 40.51 Million USD | 443.15% |
| MEI Pharma, Inc. | 26.38 Million USD | 627.043% |
| NextCure, Inc. | -59.03 Million USD | -135.495% |
| Onconetix, Inc. | -36.7 Million USD | -278.77% |
| Oncternal Therapeutics, Inc. | 2.23 Million USD | 6320.761% |
| Opthea Limited | -200.01 Million USD | 30.49% |
| Psyence Biomedical Ltd. | -2.75 Million USD | -4952.879% |
| Vaxcyte, Inc. | -464.88 Million USD | 70.093% |
| PDS Biotechnology Corporation | -40.08 Million USD | -246.848% |
| Precigen, Inc. | -89.22 Million USD | -55.822% |
| Pharming Group N.V. | 9.87 Million USD | 1507.654% |
| Phathom Pharmaceuticals, Inc. | -159.04 Million USD | 12.584% |
| Pieris Pharmaceuticals, Inc. | -22.76 Million USD | -510.816% |
| PureTech Health plc | -11.62 Million USD | -1095.786% |
| Rigel Pharmaceuticals, Inc. | -16.98 Million USD | -718.762% |
| Avidity Biosciences, Inc. | -233.49 Million USD | 40.456% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.11 Million USD | -476.62% |
| Sangamo Therapeutics, Inc. | -87.42 Million USD | -59.029% |
| Sol-Gel Technologies Ltd. | -28.96 Million USD | -380.04% |
| Acelyrin, Inc. | -381.52 Million USD | 63.558% |
| Salarius Pharmaceuticals, Inc. | -12.88 Thousand USD | -1078946.853% |
| Summit Therapeutics Inc. | 1 Million USD | 13989.51% |
| Sensei Biotherapeutics, Inc. | -33.38 Million USD | -316.444% |
| Senti Biosciences, Inc. | -61.33 Million USD | -126.676% |
| Stoke Therapeutics, Inc. | -112.3 Million USD | -23.801% |
| Elevation Oncology, Inc. | -41.46 Million USD | -235.288% |
| Alaunos Therapeutics, Inc. | -30.9 Million USD | -349.89% |
| Telomir Pharmaceuticals, Inc. Common Stock | -6.11 Million USD | -2173.08% |
| Entrada Therapeutics, Inc. | -321 Thousand USD | -43212.773% |
| VistaGen Therapeutics, Inc. | -32.45 Million USD | -328.416% |
| Kintara Therapeutics, Inc. | -8.39 Million USD | -1555.955% |
| Wave Life Sciences Ltd. | -58.79 Million USD | -136.493% |
| Seer, Inc. | -97.88 Million USD | -42.038% |
| Verrica Pharmaceuticals Inc. | -62.19 Million USD | -123.538% |
| Aadi Bioscience, Inc. | -65.36 Million USD | -112.704% |
| ESSA Pharma Inc. | -26.45 Million USD | -425.543% |
| GlycoMimetics, Inc. | -39.12 Million USD | -255.386% |
| GT Biopharma, Inc. | 5.97 Million USD | 2425.372% |
| Inhibrx Biosciences, Inc. | -206.69 Million USD | 32.734% |
| Akebia Therapeutics, Inc. | -6.86 Million USD | -1924.374% |
| Catalyst Pharmaceuticals, Inc. | 86.81 Million USD | 260.155% |
| Longboard Pharmaceuticals, Inc. | -56.75 Million USD | -144.977% |
| Orchestra BioMed Holdings, Inc. | -51.21 Million USD | -171.45% |
| Alzamend Neuro, Inc. | -9.88 Million USD | -1306.244% |
| Sorrento Therapeutics, Inc. | -539.92 Million USD | 74.25% |
| TRACON Pharmaceuticals, Inc. | -6.88 Million USD | -1919.669% |
| Viracta Therapeutics, Inc. | -46.86 Million USD | -196.688% |
| Rocket Pharmaceuticals, Inc. | -236.62 Million USD | 41.242% |
| Aptose Biosciences Inc. | -52.26 Million USD | -166.002% |
| ZyVersa Therapeutics, Inc. | -107.74 Million USD | -29.042% |
| Soligenix, Inc. | -7.85 Million USD | -1670.491% |
| Century Therapeutics, Inc. | -121.2 Million USD | -14.707% |
| Kura Oncology, Inc. | -164.95 Million USD | 15.714% |
| TScan Therapeutics, Inc. | -80.09 Million USD | -73.58% |
| Intensity Therapeutics, Inc. | -10.08 Million USD | -1278.485% |
| Ocean Biomedical, Inc. | -957.73 Thousand USD | -14416.899% |
| CytomX Therapeutics, Inc. | -4.3 Million USD | -3126.595% |
| Autolus Therapeutics plc | -156.77 Million USD | 11.313% |
| Mineralys Therapeutics, Inc. | -84.65 Million USD | -64.232% |
| EyePoint Pharmaceuticals, Inc. | -69 Million USD | -101.496% |
| Eterna Therapeutics Inc. | -19.93 Million USD | -597.472% |
| Adaptive Biotechnologies Corporation | -189.27 Million USD | 26.543% |
| GRI Bio, Inc. | -10.89 Million USD | -1175.775% |
| Xenetic Biosciences, Inc. | -4.51 Million USD | -2978.892% |
| Tenaya Therapeutics, Inc. | -122.5 Million USD | -13.492% |
| IGM Biosciences, Inc. | -253.35 Million USD | 45.124% |
| INmune Bio, Inc. | - USD | Infinity% |
| Heron Therapeutics, Inc. | -103.79 Million USD | -33.954% |
| SAB Biotherapeutics, Inc. | -38.13 Million USD | -264.601% |
| Pasithea Therapeutics Corp. | -15.33 Million USD | -806.887% |
| Entero Therapeutics, Inc. | -15.74 Million USD | -783.134% |
| Milestone Pharmaceuticals Inc. | -56.84 Million USD | -144.584% |
| X4 Pharmaceuticals, Inc. | -107.1 Million USD | -29.813% |
| Atara Biotherapeutics, Inc. | -265.99 Million USD | 47.731% |
| Coherus BioSciences, Inc. | -193.93 Million USD | 28.31% |
| Verastem, Inc. | -83.16 Million USD | -67.176% |
| Abeona Therapeutics Inc. | -50.57 Million USD | -174.923% |
| Pliant Therapeutics, Inc. | -158.22 Million USD | 12.131% |
| Tonix Pharmaceuticals Holding Corp. | -114.08 Million USD | -21.865% |
| Histogen Inc. | -10.5 Million USD | -1223.755% |
| Aprea Therapeutics, Inc. | -14.27 Million USD | -873.647% |
| Surrozen, Inc. | -41.13 Million USD | -238.027% |
| Organovo Holdings, Inc. | -14.8 Million USD | -839.038% |
| Lixte Biotechnology Holdings, Inc. | 3207.00 USD | 4335428.968% |
| Ovid Therapeutics Inc. | -58.71 Million USD | -136.802% |
| Panbela Therapeutics, Inc. | -51.29 Million USD | -171.053% |
| CASI Pharmaceuticals, Inc. | -21.53 Million USD | -545.499% |
| Cadrenal Therapeutics, Inc. Common Stock | -8.33 Million USD | -1567.473% |
| Centessa Pharmaceuticals plc | -166.06 Million USD | 16.278% |
| Hepion Pharmaceuticals, Inc. | -49.25 Million USD | -182.254% |
| Arcturus Therapeutics Holdings Inc. | -24.16 Million USD | -475.329% |
| BioRestorative Therapies, Inc. | -15.05 Million USD | -823.505% |
| Apollomics, Inc. | -171.74 Million USD | 19.047% |
| Amarin Corporation plc | -50.9 Million USD | -173.143% |
| Mesoblast Limited | -61.33 Million USD | -126.694% |
| Turnstone Biologics Corp. | -56.23 Million USD | -147.242% |
| Kymera Therapeutics, Inc. | -143.2 Million USD | 2.91% |
| Synaptogenix, Inc. | -8.3 Million USD | -1573.595% |
| Tiziana Life Sciences Ltd | -15.33 Million USD | -806.409% |
| Aurinia Pharmaceuticals Inc. | -63.04 Million USD | -120.524% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | -2801.701% |
| Monopar Therapeutics Inc. | 429.03 Thousand USD | 32505.912% |
| Exelixis, Inc. | 196.6 Million USD | 170.719% |
| Better Therapeutics, Inc. | -38.26 Million USD | -263.374% |
| Nurix Therapeutics, Inc. | -141.4 Million USD | 1.68% |
| Apellis Pharmaceuticals, Inc. | -495.21 Million USD | 71.924% |
| NLS Pharmaceutics AG | -11.79 Million USD | -1078.688% |
| Dermata Therapeutics, Inc. | 247.21 Thousand USD | 56339.887% |
| Aridis Pharmaceuticals, Inc. | -29.5 Million USD | -371.206% |
| Gritstone bio, Inc. | -126.86 Million USD | -9.594% |
| Jasper Therapeutics, Inc. | -64.98 Million USD | -113.948% |
| TNF Pharmaceuticals, Inc. | -3.99 Million USD | -3375.897% |
| Avid Bioservices, Inc. | -11.48 Million USD | -1110.992% |
| Insmed Incorporated | -654.73 Million USD | 78.765% |
| Virpax Pharmaceuticals, Inc. | -2.24 Million USD | -6080.061% |
| MediWound Ltd. | -4.89 Million USD | -2741.488% |
| OmniAb, Inc. | -49.73 Million USD | -179.572% |
| Alector, Inc. | -142.89 Million USD | 2.7% |
| Seres Therapeutics, Inc. | -85.43 Million USD | -62.738% |
| Checkpoint Therapeutics, Inc. | -52.14 Million USD | -166.614% |
| Zai Lab Limited | -366.57 Million USD | 62.072% |
| Revance Therapeutics, Inc. | -290.63 Million USD | 52.162% |
| Aura Biosciences, Inc. | -83.69 Million USD | -66.118% |
| Lyell Immunopharma, Inc. | -225.24 Million USD | 38.275% |
| Immunic, Inc. | -99.11 Million USD | -40.28% |
| Tarsus Pharmaceuticals, Inc. | -131.67 Million USD | -5.593% |
| Veracyte, Inc. | -49.4 Million USD | -181.394% |
| InMed Pharmaceuticals Inc. | -7.06 Million USD | -1868.224% |
| FibroGen, Inc. | -261.4 Million USD | 46.813% |
| SeaStar Medical Holding Corporation | -11.14 Million USD | -1147.949% |
| Adial Pharmaceuticals, Inc. | -7 Million USD | -1885.823% |
| Sonnet BioTherapeutics Holdings, Inc. | -18.71 Million USD | -642.827% |
| Jazz Pharmaceuticals plc | 1.44 Billion USD | 109.592% |
| Cyclacel Pharmaceuticals, Inc. | -25.42 Million USD | -446.904% |
| Amylyx Pharmaceuticals, Inc. | 39.89 Million USD | 448.543% |
| TG Therapeutics, Inc. | 26.1 Million USD | 632.697% |
| Galecto, Inc. | -37.51 Million USD | -270.57% |
| Calithera Biosciences, Inc. | -38.26 Million USD | -263.345% |
| Fortrea Holdings Inc. | 167.3 Million USD | 183.105% |
| KalVista Pharmaceuticals, Inc. | -134.28 Million USD | -3.54% |
| Aptevo Therapeutics Inc. | -28.31 Million USD | -391.095% |
| XBiotech Inc. | -35.76 Million USD | -288.732% |
| Jasper Therapeutics, Inc. | -64.98 Million USD | -113.948% |
| Lyra Therapeutics, Inc. | -65.25 Million USD | -113.079% |
| Foghorn Therapeutics Inc. | -104.45 Million USD | -33.104% |
| Y-mAbs Therapeutics, Inc. | -25.67 Million USD | -441.578% |
| Theravance Biopharma, Inc. | -40.86 Million USD | -240.211% |
| Ultragenyx Pharmaceutical Inc. | -516.45 Million USD | 73.079% |
| Metagenomi, Inc. Common Stock | -56.02 Million USD | -148.182% |
| Vaxxinity, Inc. | -56.05 Thousand USD | -247949.098% |
| BioCryst Pharmaceuticals, Inc. | -116.33 Million USD | -19.512% |
| Gain Therapeutics, Inc. | -22.16 Million USD | -527.139% |
| Cartesian Therapeutics, Inc. | -235.06 Million USD | 40.853% |
| NexImmune, Inc. | -28.16 Million USD | -393.597% |
| Creative Medical Technology Holdings, Inc. | -5.52 Million USD | -2416.203% |
| Marker Therapeutics, Inc. | -11.79 Million USD | -1079.026% |
| Regeneron Pharmaceuticals, Inc. | 4.65 Billion USD | 102.987% |
| Chemomab Therapeutics Ltd. | -25.39 Million USD | -447.55% |
| Scopus BioPharma Inc. | -11.71 Million USD | -1086.991% |
| RAPT Therapeutics, Inc. | -125.84 Million USD | -10.479% |
| Ainos, Inc. | -8.77 Million USD | -1484.777% |
| Pluri Inc. | -20.22 Million USD | -587.436% |
| Prothena Corporation plc | -190.1 Million USD | 26.866% |
| Adaptimmune Therapeutics plc | -128.19 Million USD | -8.453% |
| Celularity Inc. | -183.94 Million USD | 24.416% |
| Rallybio Corporation | -72.37 Million USD | -92.108% |
| Cue Biopharma, Inc. | -46.05 Million USD | -201.907% |
| MeiraGTx Holdings plc | -57.05 Million USD | -143.697% |
| Omeros Corporation | -163.61 Million USD | 15.021% |
| Humacyte, Inc. | -96.45 Million USD | -44.139% |
| Immunocore Holdings plc | -59.64 Million USD | -133.087% |
| Cocrystal Pharma, Inc. | -19.37 Million USD | -617.706% |
| Cidara Therapeutics, Inc. | -24.36 Million USD | -470.63% |
| Blueprint Medicines Corporation | -474.61 Million USD | 70.706% |
| CalciMedica, Inc. | -34.18 Million USD | -306.663% |
| Cabaletta Bio, Inc. | -73.23 Million USD | -89.849% |
| Marinus Pharmaceuticals, Inc. | -125.49 Million USD | -10.787% |
| Scholar Rock Holding Corporation | -168.45 Million USD | 17.463% |
| Sana Biotechnology, Inc. | -252.39 Million USD | 44.913% |
| Pulmatrix, Inc. | -12.64 Million USD | -999.431% |
| Elicio Therapeutics, Inc. | -32.96 Million USD | -321.75% |
| Vigil Neuroscience, Inc. | -88.46 Million USD | -57.159% |
| Intellia Therapeutics, Inc. | -506.31 Million USD | 72.54% |
| Adlai Nortye Ltd. American Depositary Shares | -101.21 Million USD | -37.365% |
| Cytokinetics, Incorporated | -456.68 Million USD | 69.556% |
| Eloxx Pharmaceuticals, Inc. | -33.37 Million USD | -316.606% |
| Nutriband Inc. | -5.12 Million USD | -2614.566% |
| Protara Therapeutics, Inc. | -43.27 Million USD | -221.302% |
| Vor Biopharma Inc. | -114.37 Million USD | -21.564% |
| Roivant Sciences Ltd. | -996.51 Million USD | 86.048% |
| Evogene Ltd. | -23.2 Million USD | -499.181% |
| ProKidney Corp. | -147.66 Million USD | 5.848% |
| Applied Therapeutics, Inc. | -64.53 Million USD | -115.44% |
| Hoth Therapeutics, Inc. | -153.14 Thousand USD | -90683.485% |
| BridgeBio Pharma, Inc. | -565.46 Million USD | 75.413% |
| CorMedix Inc. | -48.88 Million USD | -184.399% |
| BioLineRx Ltd. | -57.06 Million USD | -143.659% |
| Tango Therapeutics, Inc. | -111.75 Million USD | -24.406% |
| Galectin Therapeutics Inc. | -202 Thousand USD | -68728.713% |
| Atai Life Sciences N.V. | -36.31 Million USD | -282.898% |
| Renovaro Biosciences Inc. | -79.51 Million USD | -74.848% |
| Aerovate Therapeutics, Inc. | -81.31 Million USD | -70.986% |
| Zentalis Pharmaceuticals, Inc. | -275.5 Million USD | 49.534% |
| Sagimet Biosciences Inc. | -30.74 Million USD | -352.29% |
| MediciNova, Inc. | -9.87 Million USD | -1307.231% |
| Praxis Precision Medicines, Inc. | -125.94 Million USD | -10.396% |
| Cardio Diagnostics Holdings, Inc. | -1.53 Million USD | -8985.996% |
| GeoVax Labs, Inc. | -26.66 Million USD | -421.336% |
| Axsome Therapeutics, Inc. | -224.99 Million USD | 38.205% |
| Biomea Fusion, Inc. | -124.62 Million USD | -11.566% |
| PTC Therapeutics, Inc. | -330.34 Million USD | 57.912% |
| Mereo BioPharma Group plc | -26.05 Million USD | -433.597% |
| Cullinan Oncology, Inc. | -190.33 Million USD | 26.955% |
| Syndax Pharmaceuticals, Inc. | -229.94 Million USD | 39.535% |
| Absci Corporation | -95.45 Million USD | -45.651% |
| NRx Pharmaceuticals, Inc. | -30.02 Million USD | -363.061% |
| 4D Molecular Therapeutics, Inc. | -107.11 Million USD | -29.795% |
| Dyne Therapeutics, Inc. | -233.47 Million USD | 40.45% |
| Kiniksa Pharmaceuticals, Ltd. | -22.85 Million USD | -508.331% |
| Ventyx Biosciences, Inc. | -207.83 Million USD | 33.104% |
| Allakos Inc. | -189.91 Million USD | 26.791% |
| Imunon, Inc. | -19.87 Million USD | -599.427% |
| Fulcrum Therapeutics, Inc. | -108.49 Million USD | -28.151% |
| Corcept Therapeutics Incorporated | 108.32 Million USD | 228.35% |
| BioAtla, Inc. | -122.24 Million USD | -13.738% |
| NLS Pharmaceutics AG | -11.79 Million USD | -1078.688% |
| Bio-Path Holdings, Inc. | -15.76 Million USD | -782.139% |
| Allogene Therapeutics, Inc. | -300.29 Million USD | 53.701% |
| Larimar Therapeutics, Inc. | -41.44 Million USD | -235.45% |
| XOMA Corporation | -39.36 Million USD | -253.219% |
| Kezar Life Sciences, Inc. | -99.25 Million USD | -40.079% |
| Cara Therapeutics, Inc. | -117.65 Million USD | -18.176% |
| aTyr Pharma, Inc. | -52.17 Million USD | -166.461% |
| Aligos Therapeutics, Inc. | -83.81 Million USD | -65.882% |
| Akero Therapeutics, Inc. | -148.63 Million USD | 6.457% |
| Viridian Therapeutics, Inc. | -234.56 Million USD | 40.727% |
| Eliem Therapeutics, Inc. | -13.65 Million USD | -918.34% |
| EyeGate Pharmaceuticals, Inc. | -8.04 Million USD | -1628.784% |
| Akari Therapeutics, Plc | -16.8 Million USD | -727.485% |
| Tevogen Bio Holdings Inc. | 188.7 Thousand USD | 73777.573% |
| Halozyme Therapeutics, Inc. | 451.94 Million USD | 130.763% |
| Lexaria Bioscience Corp. | -6.38 Million USD | -2076.274% |
| UroGen Pharma Ltd. | -63.83 Million USD | -117.816% |
| Sutro Biopharma, Inc. | -67.91 Million USD | -104.718% |
| ZIVO Bioscience, Inc. | -7.26 Million USD | -1814.275% |
| Orgenesis Inc. | -60.71 Million USD | -128.983% |
| Entera Bio Ltd. | -8.8 Million USD | -1479.214% |
| GH Research PLC | -41.15 Million USD | -237.847% |
| Lisata Therapeutics, Inc. | -25.51 Million USD | -444.825% |
| Reneo Pharmaceuticals, Inc. | -82.23 Million USD | -69.073% |
| Xencor, Inc. | -125.87 Million USD | -10.455% |
| 60 Degrees Pharmaceuticals, Inc. | -1.42 Million USD | -9646.205% |
| Replimune Group, Inc. | -230.19 Million USD | 39.602% |
| Coeptis Therapeutics Holdings, Inc. | -20.15 Million USD | -589.734% |
| Vanda Pharmaceuticals Inc. | -10.94 Million USD | -1170.645% |
| Lexaria Bioscience Corp. | -6.38 Million USD | -2076.274% |
| Portage Biotech Inc. | -18.19 Million USD | -663.965% |
| Cardio Diagnostics Holdings, Inc. | -1.53 Million USD | -8985.996% |
| Olema Pharmaceuticals, Inc. | -104.58 Million USD | -32.94% |
| OncoCyte Corporation | -23.12 Million USD | -501.28% |
| Qualigen Therapeutics, Inc. | -11.3 Million USD | -1130.35% |
| Processa Pharmaceuticals, Inc. | -11.45 Million USD | -1113.546% |
| Purple Biotech Ltd. | -22.22 Million USD | -525.575% |
| CollPlant Biotechnologies Ltd. | -6.41 Million USD | -2069.017% |
| scPharmaceuticals Inc. | -46.06 Million USD | -201.848% |
| ProMIS Neurosciences, Inc. | -17.8 Million USD | -680.665% |
| HilleVax, Inc. | -132.46 Million USD | -4.958% |
| NeuroSense Therapeutics Ltd. | -10.63 Million USD | -1207.571% |
| Tharimmune, Inc. | -9.3 Million USD | -1394.573% |
| Genprex, Inc. | -31.06 Million USD | -347.622% |
| Neumora Therapeutics, Inc. Common Stock | -187.52 Million USD | 25.859% |
| Atossa Therapeutics, Inc. | -31.35 Million USD | -343.433% |
| XTL Biopharmaceuticals Ltd. | -764 Thousand USD | -18098.168% |
| Virios Therapeutics, Inc. | 150.9 Thousand USD | 92234.072% |
| OKYO Pharma Limited | -15.74 Thousand USD | -882887.094% |
| Savara Inc. | -59.13 Million USD | -135.121% |
| Curis, Inc. | -45.13 Million USD | -208.013% |
| Daré Bioscience, Inc. | -30.7 Million USD | -352.857% |
| Carmell Therapeutics Corporation | -15.19 Million USD | -815.23% |
| Titan Pharmaceuticals, Inc. | -7.16 Million USD | -1840.461% |
| Achieve Life Sciences, Inc. | -26.73 Million USD | -420.064% |
| BeiGene, Ltd. | -1.12 Billion USD | 87.637% |
| Kiromic BioPharma, Inc. | -16.3 Million USD | -752.907% |
| Revolution Medicines, Inc. Warrant | -430.58 Million USD | 67.71% |
| Protagonist Therapeutics, Inc. | -90.34 Million USD | -53.901% |
| Erasca, Inc. | -121.31 Million USD | -14.611% |
| bluebird bio, Inc. | -167.16 Million USD | 16.826% |
| Protagenic Therapeutics, Inc. | -4.49 Million USD | -2990.499% |
| BioMarin Pharmaceutical Inc. | 310.28 Million USD | 144.809% |
| DBV Technologies S.A. | -85.98 Million USD | -61.701% |
| Protagenic Therapeutics, Inc. | -4.49 Million USD | -2990.499% |
| Moderna, Inc. | -3.28 Billion USD | 95.765% |
| Vincerx Pharma, Inc. | -42.6 Million USD | -226.302% |
| Fresh Tracks Therapeutics, Inc. | -5.64 Million USD | -2361.65% |
| Molecular Templates, Inc. | 1.43 Million USD | 9822.657% |
| Acrivon Therapeutics, Inc. Common Stock | -59.85 Million USD | -132.296% |
| Travere Therapeutics, Inc. | -326.24 Million USD | 57.384% |
| Monte Rosa Therapeutics, Inc. | -137.08 Million USD | -1.419% |
| Spruce Biosciences, Inc. | -47.36 Million USD | -193.531% |
| Cogent Biosciences, Inc. | -205.86 Million USD | 32.462% |
| MacroGenics, Inc. | 2.01 Million USD | 6993.109% |
| RenovoRx, Inc. | -11.39 Million USD | -1120.667% |
| Adicet Bio, Inc. | -136.53 Million USD | -1.83% |
| Prime Medicine, Inc. | -193.75 Million USD | 28.244% |
| Aditxt, Inc. | -25.45 Million USD | -446.132% |
| Adagene Inc. | -14.95 Million USD | -829.944% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | -1801.944% |
| Quantum-Si incorporated | -91.8 Million USD | -51.447% |
| Maravai LifeSciences Holdings, Inc. | 712.4 Million USD | 119.516% |
| Acurx Pharmaceuticals, Inc. | - USD | Infinity% |
| Voyager Therapeutics, Inc. | 126.45 Million USD | 209.947% |
| SciSparc Ltd. | -5.28 Million USD | -2532.223% |
| Vericel Corporation | 2.86 Million USD | 4954.539% |
| Revelation Biosciences, Inc. | -95.2 Thousand USD | -145931.846% |
| Minerva Neurosciences, Inc. | -21.69 Million USD | -540.963% |
| Generation Bio Co. | -133.3 Million USD | -4.302% |
| Astria Therapeutics, Inc. | -83.03 Million USD | -67.45% |
| Black Diamond Therapeutics, Inc. | -86.02 Million USD | -61.624% |
| Arcutis Biotherapeutics, Inc. | -227.43 Million USD | 38.868% |
| Invivyd, Inc. | -196.61 Million USD | 29.286% |
| Relay Therapeutics, Inc. | -374.15 Million USD | 62.84% |
| Quoin Pharmaceuticals, Ltd. | -9.27 Million USD | -1399.052% |
| Spero Therapeutics, Inc. | 27.15 Million USD | 612.02% |
| Artelo Biosciences, Inc. | -10.28 Million USD | -1251.813% |
| 2seventy bio, Inc. | -206.41 Million USD | 32.644% |
| ADMA Biologics, Inc. | 5.12 Million USD | 2815.508% |
| Clene Inc. | -43.24 Million USD | -221.533% |
| Capricor Therapeutics, Inc. | -23 Million USD | -504.26% |
| Boundless Bio, Inc. Common Stock | -48.47 Million USD | -186.804% |
| GeoVax Labs, Inc. | -26.66 Million USD | -421.336% |
| Recursion Pharmaceuticals, Inc. | -299.56 Million USD | 53.588% |
| Citius Pharmaceuticals, Inc. | -36.72 Million USD | -278.537% |
| Contineum Therapeutics, Inc. Class A Common Stock | 23.57 Million USD | 689.802% |
| Relmada Therapeutics, Inc. | 4.91 Million USD | 2931.503% |
| Finch Therapeutics Group, Inc. | -32.48 Million USD | -328.034% |
| ALX Oncology Holdings Inc. | -158.4 Million USD | 12.228% |
| Vir Biotechnology, Inc. | -684.3 Million USD | 79.682% |
| Evaxion Biotech A/S | -21.4 Million USD | -549.601% |
| Ocular Therapeutix, Inc. | -66.41 Million USD | -109.341% |
| Verve Therapeutics, Inc. | -217.66 Million USD | 36.126% |
| Trevena, Inc. | -35.28 Million USD | -293.998% |
| Surrozen, Inc. | -41.13 Million USD | -238.027% |
| Tyra Biosciences, Inc. | -79.59 Million USD | -74.683% |
| Cingulate Inc. | -22.95 Million USD | -505.759% |
| Galmed Pharmaceuticals Ltd. | -7.46 Million USD | -1763.477% |
| Unity Biotechnology, Inc. | -37.28 Million USD | -272.915% |
| Tenax Therapeutics, Inc. | -8.22 Million USD | -1590.101% |
| Terns Pharmaceuticals, Inc. | -102.26 Million USD | -35.953% |
| ACADIA Pharmaceuticals Inc. | -67.82 Million USD | -104.983% |
| Connect Biopharma Holdings Limited | -58.37 Million USD | -138.186% |
| Clearmind Medicine Inc. | -8.71 Million USD | -1496.136% |
| Kronos Bio, Inc. | -121.83 Million USD | -14.121% |
| Bolt Biotherapeutics, Inc. | -74.34 Million USD | -87.019% |
| CERo Therapeutics Holdings, Inc. | -2.44 Million USD | -5594.815% |
| Viking Therapeutics, Inc. | -100.82 Million USD | -37.894% |
| Statera Biopharma, Inc. | 38.93 Million USD | 457.093% |
| ImmunityBio, Inc. | -436.18 Million USD | 68.125% |
| Korro Bio, Inc. | -80.9 Million USD | -71.851% |
| Kineta, Inc. | -15.71 Million USD | -784.778% |
| BioVie Inc. | -31.95 Million USD | -335.158% |
| Codexis, Inc. | -49.28 Million USD | -182.114% |
| Celularity Inc. | -183.94 Million USD | 24.416% |
| Crinetics Pharmaceuticals, Inc. | -221.51 Million USD | 37.234% |
| Celcuity Inc. | -58.3 Million USD | -138.44% |
| Virax Biolabs Group Limited | -6.6 Million USD | -2003.661% |
| Cibus, Inc. | -314.58 Million USD | 55.804% |
| Eledon Pharmaceuticals, Inc. | - USD | Infinity% |
| eFFECTOR Therapeutics, Inc. | -33.73 Million USD | -312.16% |
| IN8bio, Inc. | -28.5 Million USD | -387.77% |
| Kodiak Sciences Inc. | -259.02 Million USD | 46.324% |
| Annexon, Inc. | -141.57 Million USD | 1.795% |
| Adverum Biotechnologies, Inc. | -112.59 Million USD | -23.477% |
| Assembly Biosciences, Inc. | -64.19 Million USD | -116.577% |
| Avalo Therapeutics, Inc. | -27.95 Million USD | -397.349% |
| Ionis Pharmaceuticals, Inc. | -230.01 Million USD | 39.553% |
| Eyenovia, Inc. | -24.1 Million USD | -476.76% |
| Puma Biotechnology, Inc. | 44.78 Million USD | 410.455% |
| Conduit Pharmaceuticals Inc. | -324 Thousand USD | -42811.728% |
| Xilio Therapeutics, Inc. | -73.8 Million USD | -88.383% |
| Arcellx, Inc. | -64.14 Million USD | -116.75% |
| Cardiff Oncology, Inc. | -45.01 Million USD | -208.868% |
| Enanta Pharmaceuticals, Inc. | -123.47 Million USD | -12.6% |
| Regulus Therapeutics Inc. | -30.88 Million USD | -350.21% |
| Moolec Science SA | -52.07 Million USD | -166.985% |
| Acumen Pharmaceuticals, Inc. | -51.6 Million USD | -169.414% |
| Geron Corporation | -174.78 Million USD | 20.453% |
| LAVA Therapeutics N.V. | -40.41 Million USD | -243.999% |
| Royalty Pharma plc | 1.88 Billion USD | 107.367% |
| Atea Pharmaceuticals, Inc. | -119.59 Million USD | -16.256% |
| Greenwich LifeSciences, Inc. | -9.32 Million USD | -1391.101% |
| TFF Pharmaceuticals, Inc. | -20.74 Million USD | -570.342% |
| Mersana Therapeutics, Inc. | -166.08 Million USD | 16.285% |
| Humacyte, Inc. | -96.45 Million USD | -44.139% |
| Structure Therapeutics Inc. | -102.45 Million USD | -35.697% |
| 89bio, Inc. | -134.46 Million USD | -3.399% |
| PMV Pharmaceuticals, Inc. | -78.87 Million USD | -76.271% |
| Avenue Therapeutics, Inc. | 4.05 Million USD | 3531.244% |
| Genelux Corporation | -24.16 Million USD | -475.353% |
| Trevi Therapeutics, Inc. | -33.8 Million USD | -311.343% |
| Lexicon Pharmaceuticals, Inc. | -163.46 Million USD | 14.945% |
| Notable Labs, Ltd. | -14.4 Million USD | -865.514% |
| Liquidia Corporation | -70.05 Million USD | -98.475% |
| Mustang Bio, Inc. | -48.06 Million USD | -189.274% |
| Immunovant, Inc. | -269.97 Million USD | 48.502% |
| Quantum-Si incorporated | -91.8 Million USD | -51.447% |
| Arbutus Biopharma Corporation | -70.98 Million USD | -95.861% |
| DiaMedica Therapeutics Inc. | -19.3 Million USD | -620.085% |
| Vera Therapeutics, Inc. | -102.01 Million USD | -36.292% |
| Acasti Pharma Inc. | -11.3 Million USD | -1130.281% |
| MiNK Therapeutics, Inc. | -22.25 Million USD | -524.781% |
| Pasithea Therapeutics Corp. | -15.33 Million USD | -806.887% |
| Xenon Pharmaceuticals Inc. | -210.51 Million USD | 33.955% |
| Elevai Labs, Inc. Common Stock | -4.27 Million USD | -3155.804% |
| NeuroBo Pharmaceuticals, Inc. | -15.88 Million USD | -775.529% |
| Tempest Therapeutics, Inc. | -28.77 Million USD | -383.16% |
| Soleno Therapeutics, Inc. | -37.03 Million USD | -275.463% |
| PepGen Inc. | -83.58 Million USD | -66.344% |
| Moleculin Biotech, Inc. | -29.5 Million USD | -371.238% |
| United Therapeutics Corporation | 1.38 Billion USD | 110.026% |
| Nuvectis Pharma, Inc. | -22.89 Million USD | -507.215% |
| Solid Biosciences Inc. | -93.43 Million USD | -48.805% |
| BriaCell Therapeutics Corp. | -4.77 Million USD | -2813.698% |
| Immuneering Corporation | -58.06 Million USD | -139.463% |
| Lixte Biotechnology Holdings, Inc. | 3207.00 USD | 4335428.968% |
| Silo Pharma, Inc. | -3.62 Million USD | -3734.137% |
| Belite Bio, Inc | -31.52 Million USD | -340.972% |
| XOMA Corporation | -39.36 Million USD | -253.219% |
| ARS Pharmaceuticals, Inc. | -67.44 Million USD | -106.138% |
| Bionomics Limited | -9.83 Million USD | -1313.379% |
| Apogee Therapeutics, Inc. | -83.98 Million USD | -65.546% |
| Alpha Tau Medical Ltd. | -34.6 Million USD | -301.763% |
| uniQure N.V. | -253.1 Million USD | 45.068% |
| Cassava Sciences, Inc. | -95.68 Million USD | -45.301% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | -1801.944% |
| Poseida Therapeutics, Inc. | -129.5 Million USD | -7.359% |
| Forte Biosciences, Inc. | -32.47 Million USD | -328.1% |
| Anebulo Pharmaceuticals, Inc. | -8.05 Million USD | -1627.029% |
| Enlivex Therapeutics Ltd. | -28.21 Million USD | -392.696% |
| Conduit Pharmaceuticals Inc. | -324 Thousand USD | -42811.728% |
| SeaStar Medical Holding Corporation | -11.14 Million USD | -1147.949% |
| FibroBiologics, Inc. Common Stock | -15.9 Million USD | -774.373% |
| Altimmune, Inc. | -87.93 Million USD | -58.11% |
| Amicus Therapeutics, Inc. | -92.07 Million USD | -50.994% |
| Alpha Tau Medical Ltd. | -34.6 Million USD | -301.763% |
| Compugen Ltd. | -12.51 Million USD | -1010.85% |
| Peak Bio, Inc. | -1356.23 USD | -10251406.013% |
| Zevra Therapeutics, Inc. | -48.59 Million USD | -186.09% |
| Benitec Biopharma Inc. | -22.49 Million USD | -518.204% |
| Spyre Therapeutics, Inc. | -242.3 Million USD | 42.62% |
| NKGen Biotech, Inc. Common Stock | -28.54 Million USD | -387.104% |
| Zura Bio Limited | -60.56 Million USD | -129.569% |
| PolyPid Ltd. | -20.26 Million USD | -586.147% |
| Aileron Therapeutics, Inc. | -15.61 Million USD | -790.502% |
| NKGen Biotech, Inc. Warrants | -28.54 Million USD | -387.104% |
| Instil Bio, Inc. | -146.12 Million USD | 4.851% |
| argenx SE | -216.02 Million USD | 35.639% |
| Immunome, Inc. | -28.27 Million USD | -391.79% |
| Compass Therapeutics, Inc. | -48.47 Million USD | -186.828% |
| Verona Pharma plc | -52.46 Million USD | -164.99% |
| enGene Holdings Inc. Warrants | -94.77 Million USD | -46.704% |
| Shattuck Labs, Inc. | -87.61 Million USD | -58.687% |
| CervoMed Inc. | -2.17 Million USD | -6301.568% |
| LENZ Therapeutics, Inc. | -122.24 Million USD | -13.735% |
| Plus Therapeutics, Inc. | -12.69 Million USD | -995.36% |
| Dianthus Therapeutics, Inc. | -48.17 Million USD | -188.608% |
| Moolec Science SA | -52.07 Million USD | -166.985% |
| Enveric Biosciences, Inc. | -17.13 Million USD | -711.168% |
| Inovio Pharmaceuticals, Inc. | -130.39 Million USD | -6.629% |
| AnaptysBio, Inc. | -143.16 Million USD | 2.885% |
| Design Therapeutics, Inc. | -66.32 Million USD | -109.625% |
| Leap Therapeutics, Inc. | -80.98 Million USD | -71.674% |
| NeurAxis, Inc. | -6.66 Million USD | -1986.19% |
| Seelos Therapeutics, Inc. | -37.75 Million USD | -268.302% |
| Lumos Pharma, Inc. | -36.57 Million USD | -280.186% |
| Achilles Therapeutics plc | -70.44 Million USD | -97.374% |
| enGene Holdings Inc. Common Stock | -94.77 Million USD | -46.704% |
| 180 Life Sciences Corp. | -22.13 Million USD | -528.146% |
| Opiant Pharmaceuticals, Inc. | 5.82 Million USD | 2485.111% |
| CERo Therapeutics Holdings, Inc. | -2.44 Million USD | -5594.815% |
| Nutriband Inc. | -5.12 Million USD | -2614.566% |
| ORIC Pharmaceuticals, Inc. | -109.74 Million USD | -26.685% |
| CG Oncology, Inc. Common stock | -55.43 Million USD | -150.819% |
| Fractyl Health, Inc. Common Stock | -50.55 Million USD | -175.043% |
| Rani Therapeutics Holdings, Inc. | -65.27 Million USD | -112.991% |
| MoonLake Immunotherapeutics | -54.1 Million USD | -156.947% |
| Palisade Bio, Inc. | -12.28 Million USD | -1032.107% |
| Tourmaline Bio, Inc. | -45.37 Million USD | -206.404% |
| Beam Therapeutics Inc. | -156.47 Million USD | 11.145% |
| Neurogene Inc. | -52.28 Million USD | -165.911% |
| Mirum Pharmaceuticals, Inc. | -136.49 Million USD | -1.864% |
| AEON Biopharma, Inc. | -48.36 Million USD | -187.492% |
| CARGO Therapeutics, Inc. Common Stock | -93.01 Million USD | -49.47% |
| Sesen Bio, Inc. | -50.84 Million USD | -173.474% |
| Enliven Therapeutics, Inc. | -81.93 Million USD | -69.694% |
| Kiora Pharmaceuticals, Inc. | -12.35 Million USD | -1025.779% |
| Iovance Biotherapeutics, Inc. | -427.43 Million USD | 67.472% |
| Taysha Gene Therapies, Inc. | -105.19 Million USD | -32.165% |
| Athira Pharma, Inc. | -116.7 Million USD | -19.135% |
| Vaccinex, Inc. | -19.74 Million USD | -604.041% |
| HCW Biologics Inc. | -23.57 Million USD | -489.725% |
| XOMA Corporation | -39.36 Million USD | -253.219% |
| Nektar Therapeutics | -243.1 Million USD | 42.81% |
| Arvinas, Inc. | -394.8 Million USD | 64.784% |
| Tevogen Bio Holdings Inc. | 188.7 Thousand USD | 73777.573% |
| Merus N.V. | -149.2 Million USD | 6.818% |
| Omega Therapeutics, Inc. | -93.49 Million USD | -48.715% |
| Quince Therapeutics, Inc. | -31.26 Million USD | -344.766% |
| Rezolute, Inc. | -68.42 Million USD | -103.198% |
| Clene Inc. | -43.24 Million USD | -221.533% |
| Indaptus Therapeutics, Inc. | -15.42 Million USD | -801.519% |
| BeyondSpring Inc. | -21.54 Million USD | -545.469% |
| Synlogic, Inc. | -55.16 Million USD | -152.051% |
| Allarity Therapeutics, Inc. | -12.08 Million USD | -1050.658% |
| Phio Pharmaceuticals Corp. | -10.64 Million USD | -1206.465% |
| Peak Bio, Inc. | -1356.23 USD | -10251406.013% |
| Werewolf Therapeutics, Inc. | -32.46 Million USD | -328.258% |
| Krystal Biotech, Inc. | 17.9 Million USD | 876.553% |
| Karyopharm Therapeutics Inc. | -118.42 Million USD | -17.405% |
| SpringWorks Therapeutics, Inc. | -341.34 Million USD | 59.269% |
| Lipella Pharmaceuticals Inc. | -4.6 Million USD | -2918.258% |
| MannKind Corporation | 15.12 Million USD | 1018.99% |
| Ikena Oncology, Inc. | -74.39 Million USD | -86.881% |
| Cyclerion Therapeutics, Inc. | -12.59 Million USD | -1004.058% |
| Gyre Therapeutics, Inc. | 20.32 Million USD | 783.987% |
| Gossamer Bio, Inc. | -172.15 Million USD | 19.238% |
| CohBar, Inc. | -12.06 Million USD | -1052.302% |
| Cognition Therapeutics, Inc. | -25.5 Million USD | -445.039% |
| NRx Pharmaceuticals, Inc. | -30.02 Million USD | -363.061% |
| Legend Biotech Corporation | -477.87 Million USD | 70.906% |
| Mural Oncology plc | -192.72 Million USD | 27.857% |
| Biora Therapeutics, Inc. | -114.05 Million USD | -21.902% |
| PaxMedica, Inc. Common Stock | -16.14 Million USD | -761.144% |
| Disc Medicine, Inc. | -91.02 Million USD | -52.743% |
| Champions Oncology, Inc. | -5.05 Million USD | -2650.97% |
| REGENXBIO Inc. | -239.46 Million USD | 41.939% |
| Ensysce Biosciences, Inc. | -10.71 Million USD | -1197.178% |
| Anavex Life Sciences Corp. | -55.75 Million USD | -149.362% |
| Cellectar Biosciences, Inc. | -38.76 Million USD | -258.628% |
| Edgewise Therapeutics, Inc. | -112.8 Million USD | -23.251% |
| Vaxart, Inc. | -74.72 Million USD | -86.066% |
| PharmaCyte Biotech, Inc. | - USD | Infinity% |
| Aldeyra Therapeutics, Inc. | -35.2 Million USD | -294.89% |
| Cellectis S.A. | -98.09 Million USD | -41.734% |
| Longeveron Inc. | -20.06 Million USD | -593.091% |
| Repare Therapeutics Inc. | -114.27 Million USD | -21.668% |
| Sarepta Therapeutics, Inc. | -439.19 Million USD | 68.344% |
| Inozyme Pharma, Inc. | -74.81 Million USD | -85.845% |
| Revolution Medicines, Inc. | -430.58 Million USD | 67.71% |
| Nymox Pharmaceutical Corporation | -6.28 Million USD | -2110.749% |
| Third Harmonic Bio, Inc. | -30.78 Million USD | -351.57% |
| ArriVent BioPharma, Inc. Common Stock | -74.59 Million USD | -86.398% |
| AN2 Therapeutics, Inc. | 4.9 Million USD | 2935.692% |
| Anixa Biosciences, Inc. | -10.96 Million USD | -1167.98% |
| Vertex Pharmaceuticals Incorporated | 4.6 Billion USD | 103.019% |
| Denali Therapeutics Inc. | -179.97 Million USD | 22.747% |
| Revelation Biosciences, Inc. | -95.2 Thousand USD | -145931.846% |
| Veru Inc. | -89.97 Million USD | -54.524% |
| Corvus Pharmaceuticals, Inc. | -26.87 Million USD | -417.278% |
| Cingulate Inc. | -22.95 Million USD | -505.759% |
| Passage Bio, Inc. | -98.34 Million USD | -41.379% |
| Context Therapeutics Inc. | -25.06 Million USD | -454.792% |
| Exicure, Inc. | -15.53 Million USD | -794.742% |
| Day One Biopharmaceuticals, Inc. | -206.06 Million USD | 32.529% |
| Oramed Pharmaceuticals Inc. | -36.97 Million USD | -276.011% |
| Scinai Immunotherapeutics Ltd. | -5.96 Million USD | -2231.77% |
| Rhythm Pharmaceuticals, Inc. | -168.46 Million USD | 17.47% |
| Nuvalent, Inc. | -149.49 Million USD | 6.996% |
| ABVC BioPharma, Inc. | -8.13 Million USD | -1609.627% |
| Carisma Therapeutics, Inc. | -85.89 Million USD | -61.867% |
| Unicycive Therapeutics, Inc. | -30.17 Million USD | -360.713% |
| OmniAb, Inc. | -49.73 Million USD | -179.572% |
| Anew Medical, Inc. | -1.3 Million USD | -10588.017% |
| Fennec Pharmaceuticals Inc. | -12.36 Million USD | -1024.507% |
| Lipocine Inc. | -16.32 Million USD | -751.785% |
| Lexeo Therapeutics, Inc. Common Stock | -66.67 Million USD | -108.541% |
| Nautilus Biotechnology, Inc. | -74.3 Million USD | -87.118% |
| SAB Biotherapeutics, Inc. | -38.13 Million USD | -264.601% |
| G1 Therapeutics, Inc. | -39.01 Million USD | -256.37% |
| Bellerophon Therapeutics, Inc. | -22.18 Million USD | -526.759% |
| Sage Therapeutics, Inc. | -545.07 Million USD | 74.492% |
| Ocugen, Inc. | -64.82 Million USD | -114.469% |
| Mind Medicine (MindMed) Inc. | -92.57 Million USD | -50.193% |
| Q32 Bio Inc. | -86.5 Million USD | -60.729% |
| Brainstorm Cell Therapeutics Inc. | -16.92 Million USD | -721.374% |
| Alumis Inc. Common Stock | -156.89 Million USD | 11.381% |
| Equillium, Inc. | -12.13 Million USD | -1045.444% |
| Kyverna Therapeutics, Inc. | -58.47 Million USD | -137.779% |
| Coya Therapeutics, Inc. | -7.9 Million USD | -1659.178% |
| CNS Pharmaceuticals, Inc. | -18.86 Million USD | -637.152% |
| Galera Therapeutics, Inc. | -46.69 Million USD | -197.768% |
| Evelo Biosciences, Inc. | -106.34 Million USD | -30.739% |
| Comera Life Sciences Holdings, Inc. | -17.88 Million USD | -677.309% |
| Dominari Holdings Inc. | -22.44 Million USD | -519.581% |
| Edesa Biotech, Inc. | -8.19 Million USD | -1597.577% |
| vTv Therapeutics Inc. | -25.41 Million USD | -447.119% |
| Bio-Techne Corporation | 326.66 Million USD | 142.562% |
| Agios Pharmaceuticals, Inc. | -384.86 Million USD | 63.875% |
| Harmony Biosciences Holdings, Inc. | 216.38 Million USD | 164.252% |
| Prelude Therapeutics Incorporated | -131.1 Million USD | -6.045% |
| Candel Therapeutics, Inc. | -37.43 Million USD | -271.441% |
| iTeos Therapeutics, Inc. | -151.1 Million USD | 7.986% |
| Nkarta, Inc. | -120.48 Million USD | -15.399% |
| BioCardia, Inc. | -11.56 Million USD | -1102.716% |
| Iterum Therapeutics plc | -34.58 Million USD | -302.065% |